Table 5.
Meta-analysis of prognostic factors
| Variable (default) | N | Heterogeneity | Random effects | ||
| I2 P | P value | In (HR) (95% CI) | HR (95% CI) | ||
| Tumour size (small) | 5 | 36.4% | 0.178 | 0.19 (–0.10 to 0.48) | 1.21 (0.90 to 1.62) |
| Age (young) | 10 | 0.3% | 0.435 | 0.11 (0.00 to 0.22) | 1.12 (1.00 to 1.25) |
| LN involvement (negative) | 17 | 22.9% | 0.188 | 0.62 (0.51 to 0.72) | 1.86 (1.67 to 2.05) |
| Microvascular invasion (negative) | 7 | 0.0% | 0.470 | 0.38 (0.24 to 0.52) | 1.46 (1.27 to 1.68) |
| Perineural invasion (negative) | 12 | 0.0% | 0.656 | 0.41 (0.30 to 0.51) | 1.51 (1.35 to 1.67) |
| Portal vein resection (none) | 8 | 58.7% | 0.018 | 0.31 (0.07 to 0.55) | 1.36 (1.07 to 1.73) |
| Resection margin status (negative) | 17 | 57.1% | 0.002 | 0.63 (0.47 to 0.78) | 1.88 (1.60 to 2.18) |
| Gender (male) | 9 | 29.1% | 0.187 | 0.06 (–0.09 to 0.21) | 1.06 (0.91 to 1.23) |
| Tumour status (T1–T2) | 5 | 54.9% | 0.065 | 0.43 (0.18 to 0.68) | 1.54 (1.20 to 1.97) |
| Tumour differentiation (well differentiated) | 10 | 0.0% | 0.505 | 0.43 (0.32 to 0.54) | 1.54 (1.38 to 1.72) |
LN, lymph node.